RxDoctor Payments Data

Erika Green, APRN

Primary Care · Bellaire, TXNPI 1699227660

Payments from drug & device makers

$1,806in general payments, 2019–2025

Across 65 payments — averaging $27.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$371
  • Gilead$281
  • Boston Scientific$248
  • Amgen$201
  • Lilly USA, LLC$144
  • Inspire Medical Systems, Inc.$87
  • plus $473 from 16 others

What the payments were for

  • Food & beverage$1,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,806 in reported general payments places this provider in the 80th percentile of 563 primary care providers in Texas.

See all primary care providers in Texas

Medicare billing

Part B allowed, 2024
$11,965
Medicare patients
71
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol15$12,991
Testosterone13$1,098
Albuterol Sulfate HfaAlbuterol Sulfate54$969
Rosuvastatin Calcium36$773
Atorvastatin Calcium75$731
Olmesartan Medoxomil11$694
Fluticasone Propionate53$652
Lisinopril46$516
Metoprolol Succinate26$509
Azelastine Hcl16$483
Montelukast Sodium23$481
Nifedipine ErNifedipine18$413
Levothyroxine Sodium52$407
Amlodipine Besylate48$387
Omeprazole23$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$42$12,99115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 563 primary care providers in Texas.

Other primary care in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →